A study to find out more about borderline ovarian tumours

Cancer type:

Ovarian cancer





This study is looking at tissue samples and clinical information to learn more about borderline ovarian tumours and how to improve treatment.

Borderline ovarian tumours are not full blown cancers. They are made up of abnormal cells that may become cancer. They develop in the ovary but do not invade surrounding tissue and rarely spread.

Doctors want to find out more about borderline ovarian tumours. In this study, they will gather clinical information, samples of tumour tissue and data from follow up visits over a number of years. They will look at how tumours may be controlled by molecules in affected cells. They hope to one day be able to predict likely disease outcome (prognosis) for individual women. And work out whether women with particular changes would do well on certain treatments or not. So in future, doctors may be able to shape treatments to better suit individual women. And hopefully develop ways to prevent the disease, or to treat it better.

Taking part in this study is unlikely to change your treatment plan. But you may possibly have a longer follow up Open a glossary item period. The results of the study will be used to help people with borderline ovarian tumours in the future.

Who can enter

You can enter this study if you are being treated at a hospital where the study is open and you

  • Have a borderline ovarian tumour
  • Are willing to visit the hospital for a check up every year for as long as the team need you to
  • Are at least 18 years old

Trial design

This study will recruit between 500 and 1,000 women.

Everyone will give permission for the team to study any spare pieces of tissue they have had removed, or may have removed in the future. This would include biopsies, and any tissue from surgery that would not need to be stored by the hospital as routine. The team will treat these samples anonymously, so no one will be able to link the results to you. If you agree, the team would also like to use these samples in future research. Future testing may involve looking at genes, but the samples will still be treated anonymously.

The team will ask if they can use information from your hospital notes, and talk to you about your family medical history. They will keep all this information confidentially.

With your permission, your hospital doctor will also enter you onto a follow up program as part of this study. What these visits will involve depends on the treatment you have had so far. If you have had your womb and both ovaries removed, you will see the doctor once a year for an examination and a blood test. If you only had your ovary or tumour removed, you will see the doctor once a year for a blood test, examination and a scan called a trans vaginal ultrasound.

The team aim to continue with these visits for up to 20 years. But this depends on whether they can get more funding. At each visit the team will explain the study again and check that you are happy to stay on the study. But you can decide to stop being in the study at any time.

Hospital visits

You will visit the hospital once a year for this study, for as long as the team ask you to.

Side effects

You may have a small bruise where you gave your blood sample.



Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Dr Mona El-Bahrawy

Supported by

Experimental Cancer Medicine Centre (ECMC)
Imperial College London

Questions about cancer? Contact our information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:


Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Around 1 in 5 people take part in clinical trials

3 phases of trials

Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think

Share this page